Role of the Extended Glasgow Outcome Scale in Assessing Recovery in Brain Injury Patients

Overview of the Extended Glasgow Outcome Scale

The Extended Glasgow Outcome Scale (GOSE) provides a more granular assessment of functional recovery after traumatic brain injury, and should be used as a primary tool for evaluating patient outcomes in clinical practice and research settings, as recommended by The Lancet Neurology 1

The GOSE helps clinicians track changes in functional status over time, providing valuable information about recovery trajectories and response to interventions, with a focus on social recovery and practical aspects of daily functioning 1
The scale integrates different outcome assessments to provide a comprehensive picture of overall outcome, making it valuable for both clinical care and research, and is particularly useful in detecting small but clinically meaningful changes in functional status 1

The GOSE may not fully capture the multidimensional nature of TBI recovery, particularly cognitive, emotional, and quality of life aspects that require supplementary assessments, as noted by The Lancet Neurology 1
Missingness of outcome data can be problematic, requiring strategies to compensate for incomplete assessments, and the GOSE may still lack sensitivity to detect subtle changes in function, particularly in patients with mild TBI or those at the extremes of the scale 1

Consider using the GOSE alongside other complementary outcome measures that assess specific domains like cognition, psychological symptoms, and quality of life, as recommended by The Lancet Neurology 1

Ongoing research is focused on developing more sensitive outcome measures that build upon the GOSE framework while addressing its limitations, and integration of the GOSE with other assessment tools is being explored to create more comprehensive outcome batteries 1
Long-term studies are needed to better understand the relationship between GOSE scores and risk of later neurological diseases, as TBI may represent a modifiable risk factor for epilepsy, stroke, and neurodegenerative diseases, as noted by The Lancet Neurology 1